Cytogenetics
Comprehensive Tumor Panel 270 Genes PDL1
A comprehensive genetic test analyzing 270 genes and PDL1 expression in tumor tissue to guide personalized cancer treatment decisions.
General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.
Review status: No completed medical review is recorded for this page.
At a glance
Plan your test
- Sample
- Formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides. Confirm specific requirements with the laboratory before booking.
- Results
- Confirm turnaround time with the laboratory before booking.
- Preparation
- No specific patient preparation is required. Ensure the tumor tissue sample is properly collected and preserved according to laboratory guidelines.
Payment: M-Pesa and card options can be confirmed during booking.
Insurance & government schemes
Is this test covered for you?
We help you verify whether the Comprehensive Tumor Panel 270 Genes PDL1 test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.
Providers & schemes we can help you check
Government & public schemes
Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.
Private insurers & employer schemes
Names shown for identification only — listing does not imply partnership or guarantee of coverage.
Have these ready when we check
- Insurer or scheme name & policy / member number
- A clinician's request / prescription for the test
- Pre-authorisation letter, if your plan requires one
Free coverage check
Ask us to verify your cover
Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.
Start with fit
Is this the right test for you?
The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.
- ✓Patients diagnosed with solid tumors.
- ✓Individuals seeking personalized cancer treatment options.
- ✓Patients considering targeted therapy or immunotherapy.
- ✓Assessment of prognosis and potential treatment response.
- ✓Identification of potential clinical trial eligibility.
In plain language
What this test helps you understand
Understanding the specific genetic changes within a tumor is crucial for developing effective, personalized treatment strategies. This test provides valuable information that can help oncologists select targeted therapies, predict potential responses to treatment, and understand the likely progression of the cancer.
This test is typically considered for individuals diagnosed with cancer, particularly when seeking information to guide treatment choices or understand prognosis. It can be particularly useful in cases where standard treatments may not be effective or when exploring clinical trial options.
Medical review status
Clinical review pending
A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.
Meet the DNA Labs Kenya medical team →A simple process
What happens next?
You do not have to navigate the test alone. We help you move from question to next step.
Speak with us
We check the test and answer your questions before collection.
Give your sample
Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.
Understand your report
A counselor helps you understand the result and the next steps.
Choose your collection
Home collection or a lab visit
We will explain the sample, preparation, and next steps before anything is collected.
Home collection
Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.
Lab or hub visit
Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.
Ask about locations →Read your report
What common result terms mean
Questions people ask
Frequently asked questions
Collaboration
Open for partnership with hospitals, clinics, doctors & researchers
Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.
Hospitals & clinics
Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.
Doctors & specialists
LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.
Research institutions
Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.
Students & academic projects
Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.
Trust & transparency
Sources, standards & how this page is maintained
Standards & references
- ACMG/AMP technical standards for sequence variant interpretation
- ClinGen curation and gene–disease validity frameworks where applicable
- LOINC-coded reporting for interoperable results
- ISO 9001:2015 quality management; ISO 15189 accreditation in progress
Page provenance
- Last updated: September 27, 2026
- Medical review: not yet completed
- Written for patients & clinicians in Kenya; reviewed periodically against current guidance
Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.
Keep exploring
Related tests
Catecholamines Plasma Test
Measures epinephrine and norepinephrine levels in plasma to help detect hormonal imbalances related to conditions like hypertension and anxiety. Confirm with the laboratory before booking.
Learn more →Epstein-Barr Virus Early RNA EBERISH In Situ Hybridization Test
Detects Epstein-Barr Virus (EBV) RNA in tumor tissue to aid in the early diagnosis of EBV-related cancers like lymphomas and nasopharyngeal carcinoma.
Learn more →CA Cyfra 211 Lung Cancer Marker Test
The CA Cyfra 21-1 Lung Cancer Marker Test measures a specific protein fragment in the blood that can be elevated in lung cancer. It aids in diagnosis and monitoring.
Learn more →Breast Cancer ER PR HER2 Ki67
The Breast Cancer ER PR HER2 Ki67 test analyzes key markers in breast tumor tissue to guide personalized treatment decisions. It measures hormone receptors (ER, PR), HER2 protein, and the Ki-67 proliferation marker.
Learn more →